PT1336409E - Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. - Google Patents

Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. Download PDF

Info

Publication number
PT1336409E
PT1336409E PT03007342T PT03007342T PT1336409E PT 1336409 E PT1336409 E PT 1336409E PT 03007342 T PT03007342 T PT 03007342T PT 03007342 T PT03007342 T PT 03007342T PT 1336409 E PT1336409 E PT 1336409E
Authority
PT
Portugal
Prior art keywords
omega
snx
binding
mviia
quot
Prior art date
Application number
PT03007342T
Other languages
English (en)
Portuguese (pt)
Inventor
Gary Arthur Amstutz
Peter Isadore Adriaenssens
Ramasharma Kristipati
Mark Raymond Pettus
Stephen Scott Bowersox
Theresa Gadbois
Robert R Luther
Kishochandra Gohil
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of PT1336409E publication Critical patent/PT1336409E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
PT03007342T 1995-06-27 1996-06-26 Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. PT1336409E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
PT1336409E true PT1336409E (pt) 2007-06-29

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
PT03007342T PT1336409E (pt) 1995-06-27 1996-06-26 Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas.
PT96923511T PT835126E (pt) 1995-06-27 1996-06-26 Composicoes e formulacoes para a producao de analgesia e para a inibicao de patologias dolorosas neuropaticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT96923511T PT835126E (pt) 1995-06-27 1996-06-26 Composicoes e formulacoes para a producao de analgesia e para a inibicao de patologias dolorosas neuropaticas

Country Status (13)

Country Link
EP (2) EP1336409B1 (https=)
JP (1) JP2838073B2 (https=)
AT (2) ATE359086T1 (https=)
AU (1) AU695166B2 (https=)
CA (1) CA2224795C (https=)
DE (3) DE69627153T2 (https=)
DK (2) DK0835126T3 (https=)
ES (2) ES2283671T3 (https=)
FR (1) FR05C0027I2 (https=)
LU (1) LU91181I2 (https=)
NL (1) NL300201I2 (https=)
PT (2) PT1336409E (https=)
WO (1) WO1997001351A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP2002509080A (ja) * 1998-02-20 2002-03-26 シンジェンタ リミテッド グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US8673856B2 (en) * 2006-11-04 2014-03-18 Anygen Co., Ltd. Omega conotoxins
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009135258A1 (en) * 2008-05-06 2009-11-12 Cnsbio Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
DE122005000043I2 (de) 2006-08-03
DK0835126T3 (da) 2003-07-14
JPH09104634A (ja) 1997-04-22
JP2838073B2 (ja) 1998-12-16
ES2194998T3 (es) 2003-12-01
AU6400296A (en) 1997-01-30
EP1336409B1 (en) 2007-04-11
LU91181I2 (fr) 2005-09-06
ATE235914T1 (de) 2003-04-15
ATE359086T1 (de) 2007-05-15
NL300201I1 (nl) 2005-09-01
EP1336409A1 (en) 2003-08-20
DE122005000043I1 (de) 2006-06-29
EP0835126A1 (en) 1998-04-15
DE69637021D1 (de) 2007-05-24
DE69637021T2 (de) 2008-01-10
PT835126E (pt) 2003-07-31
AU695166B2 (en) 1998-08-06
DE69627153T2 (de) 2003-12-04
FR05C0027I1 (https=) 2005-08-12
FR05C0027I2 (https=) 2006-12-29
WO1997001351A1 (en) 1997-01-16
HK1058146A1 (en) 2004-05-07
DK1336409T3 (da) 2007-08-13
CA2224795A1 (en) 1997-01-16
CA2224795C (en) 2001-04-03
ES2283671T3 (es) 2007-11-01
NL300201I2 (nl) 2006-02-01
EP0835126B1 (en) 2003-04-02
DE69627153D1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
PT1336409E (pt) Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas.
Bennett et al. The role of voltage-gated sodium channels in pain signaling
US5795864A (en) Stable omega conopetide formulations
Taylor Agents acting at the neuromuscular junction and autonomic ganglia
US20220306704A1 (en) Neurotoxins for use in inhibiting cgrp
Sandkühler et al. Spinal somatostatin superfusion in vivo affects activity of cat nociceptive dorsal horn neurons: comparison with spinal morphine
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
Yu et al. Dexmedetomidine enhances ropivacaine-induced sciatic nerve injury in diabetic rats
US20040138204A1 (en) Compositions and methods for pain reduction
Li et al. Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA [1, 2] and GeXIVA [1, 4] in rats of neuropathic pain
Westlund et al. A rat knockout model implicates TRPC4 in visceral pain sensation
WO2018068670A1 (zh) 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
Porreca et al. Antinociceptive Pharmacology of N-[[4-(4, 5-Dihydro-1 H-imidazol-2-yl) phenyl] methyl]-2-[2-[[(4-methoxy-2, 6-dimethylphenyl) sulfonyl] methylamino] ethoxy]-N-methylacetamide, Fumarate (LF22-0542), a Novel Nonpeptidic Bradykinin B1 Receptor Antagonist
JP2011522012A (ja) ペプチドトキシンＡＰＥＴｘ２の鎮痛作用
Liu et al. Pacemaking activity in the peripheral nervous system: Physiology and roles of hyperpolarization activated and cyclic nucleotide-gated channels in neuropathic pain
Canduz et al. Epidural lornoxicam administration–innocent
Nyman et al. The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain
Zhang et al. Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level
Li et al. Acid-sensing ion channel 3 expression is increased in dorsal root ganglion, hippocampus and hypothalamus in remifentanil-induced hyperalgesia in rats
US20080112954A1 (en) Method for treating chronic pain
Goldhill et al. Mechanism of tachykinin NK3 receptor-mediated colonic ion transport in the guinea pig
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
HK1058146B (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
Vonhof et al. Tolerance and dependence following chronic intracerebroventricular infusions of Tyr-d-Arg2-Phe-Sar4 (TAPS)
Maile Sensory processing in the Isolated in vitro Rat Spinal Cord with particular emphasis on Opioid-related Peptides, Excitatory and Inhibitiory Amino Acids